

Maeve Aine Lowery

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7829384/publications.pdf>

Version: 2024-02-01

154
papers

9,883
citations

101384

36
h-index

38300

95
g-index

156
all docs

156
docs citations

156
times ranked

15774
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	15.2	2,473
2	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	1.5	1,266
3	Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , 2020, 21, 796-807.	5.1	620
4	Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 276-282.	0.8	524
5	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 825.	3.8	366
6	Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. <i>Clinical Cancer Research</i> , 2018, 24, 4154-4161.	3.2	348
7	Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. <i>Clinical Cancer Research</i> , 2018, 24, 1326-1336.	3.2	281
8	Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline <i>BRCA/PALB2</i> Mutation. <i>Journal of Clinical Oncology</i> , 2020, 38, 1378-1388.	0.8	265
9	An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known <i>BRCA</i> Mutation: Clinical Descriptors, Treatment Implications, and Future Directions. <i>Oncologist</i> , 2011, 16, 1397-1402.	1.9	227
10	Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With <i>IDH1</i> Mutation. <i>JAMA Oncology</i> , 2021, 7, 1669.	3.4	194
11	Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1067-1074.	3.0	170
12	Identification of germline genetic mutations in patients with pancreatic cancer. <i>Cancer</i> , 2015, 121, 4382-4388.	2.0	167
13	Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. <i>Clinical Cancer Research</i> , 2017, 23, 6094-6100.	3.2	161
14	Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 711-720.	3.7	161
15	Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. <i>Cancer Discovery</i> , 2018, 8, 1540-1547.	7.7	138
16	FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 3512-3521.	0.7	135
17	Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency. <i>Chinese Clinical Oncology</i> , 2016, 5, 62-62.	0.4	131
18	Phase II trial of veliparib in patients with previously treated <i>BRCA</i> -mutated pancreas ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2018, 89, 19-26.	1.3	125

#	ARTICLE	IF	CITATIONS
19	Acinar Cell Carcinoma of the Pancreas: New Genetic and Treatment Insights into a Rare Malignancy. <i>Oncologist</i> , 2011, 16, 1714-1720.	1.9	121
20	A Single-Arm, Nonrandomized Phase II Trial of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Resectable Pancreas Adenocarcinoma. <i>Annals of Surgery</i> , 2014, 260, 142-148.	2.1	121
21	Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma. <i>JAMA Oncology</i> , 2020, 6, 60.	3.4	112
22	Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. <i>Investigational New Drugs</i> , 2020, 38, 800-811.	1.2	106
23	Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline <i>BRCA</i> mutation carriers and wild-type <i>BRCA</i> pancreatic ductal adenocarcinoma. <i>Cancer</i> , 2018, 124, 1374-1382.	2.0	91
24	Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction) Trial (Modified MAGIC or FLOT protocol). (NCT01726452).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4004-4004.	0.8	87
25	Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. <i>Hepatology</i> , 2021, 74, 1429-1444.	3.6	73
26	Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4015-4015.	0.8	71
27	Preliminary study of tumor heterogeneity in imaging predicts two year survival in pancreatic cancer patients. <i>PLoS ONE</i> , 2017, 12, e0188022.	1.1	69
28	Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2020, 38, 433-444.	1.2	69
29	A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma. <i>Cancer</i> , 2017, 123, 4556-4565.	2.0	61
30	Systemic Chemotherapy Combined with Resection for Locally Advanced Gallbladder Carcinoma: Surgical and Survival Outcomes. <i>Journal of the American College of Surgeons</i> , 2017, 224, 906-916.	0.2	56
31	Pharmacogenomic Modeling of Circulating Tumor and Invasive Cells for Prediction of Chemotherapy Response and Resistance in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5281-5289.	3.2	49
32	Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes. <i>Cancer</i> , 2019, 125, 4426-4434.	2.0	49
33	A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 335-335.	0.8	42
34	Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 50-58.	2.3	41
35	Genomic Landscape of Pancreatic Adenocarcinoma in Younger versus Older Patients: Does Age Matter?. <i>Clinical Cancer Research</i> , 2019, 25, 2185-2193.	3.2	41
36	Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1-13.	1.4	39

#	ARTICLE	IF	CITATIONS
37	Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. <i>Acta Oncol</i> , 2017, 56, 1746-1753.	0.8	38
38	Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1194-1202.	3.0	35
39	DNA Mismatch Repair Abnormalities in Acinar Cell Carcinoma of the Pancreas. <i>Pancreas</i> , 2014, 43, 1264-1270.	0.5	34
40	A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model. <i>Translational Oncology</i> , 2017, 10, 760-765.	1.7	33
41	Pancreas Adenocarcinoma: Ascites, Clinical Manifestations, and Management Implications. <i>Clinical Colorectal Cancer</i> , 2016, 15, 360-368.	1.0	30
42	Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes. <i>Cancer</i> , 2019, 125, 1441-1448.	2.0	28
43	90 Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. <i>European Journal of Cancer</i> , 2015, 51, 1857-1864.	1.3	26
44	Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings. <i>Cancer</i> , 2020, 126, 1995-2002.	2.0	26
45	Treatment, Outcomes, and Clinical Trial Participation in Elderly Patients With Metastatic Pancreas Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2015, 14, 269-276.e1.	1.0	23
46	Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 937-945.	3.2	22
47	Incidence, Management, and Implications of Visceral Thrombosis in Pancreatic Ductal Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2018, 17, 121-128.	1.0	21
48	Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations. <i>JCO Precision Oncology</i> , 2021, 5, 44-50.	1.5	20
49	A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression. <i>Pancreatology</i> , 2014, 14, 398-402.	0.5	18
50	Current management and future directions in metastatic pancreatic adenocarcinoma. <i>Cancer</i> , 2016, 122, 3765-3775.	2.0	18
51	FLOT-regimen Chemotherapy and Transthoracic en bloc Resection for Esophageal and Junctional Adenocarcinoma. <i>Annals of Surgery</i> , 2021, 274, 814-820.	2.1	18
52	Moving the Needle on Precision Medicine in Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 2693-2705.	0.8	18
53	Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 819-827.	0.6	17
54	Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4023-4023.	0.8	17

#	ARTICLE	IF	CITATIONS
55	ClarIDHy: A phase 3, multicenter, randomized, double-blind study of AG-120 vs placebo in patients with an advanced cholangiocarcinoma with an IDH1 mutation.. Journal of Clinical Oncology, 2017, 35, TPS4142-TPS4142.	0.8	17
56	Novel Therapeutics for Pancreatic Adenocarcinoma. Hematology/Oncology Clinics of North America, 2015, 29, 777-787.	0.9	15
57	The Cancer-Immune Set Point in Oesophageal Cancer. Frontiers in Oncology, 2020, 10, 891.	1.3	15
58	In Vitro and In Vivo Comparison of Gemcitabine and the Gemcitabine Analog 1-(2â€²-deoxy-2â€²-fluoroarabinofuranosyl) Cytosine (FAC) in Human Orthotopic and Genetically Modified Mouse Pancreatic Cancer Models. Molecular Imaging and Biology, 2017, 19, 885-892.	1.3	14
59	Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma. Future Oncology, 2021, 17, 2057-2074.	1.1	14
60	Postresection Surveillance for Pancreatic Cancer Performance Status, Imaging, and Serum Markers. Cancer Journal (Sudbury, Mass), 2012, 18, 609-613.	1.0	13
61	Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotypeâ€™Phenotype Featuresâ€™An Entity With an Increasing Incidence?. Clinical Colorectal Cancer, 2018, 17, e315-e321.	1.0	13
62	Systemic therapy for biliary cancers. Chinese Clinical Oncology, 2016, 5, 65-65.	0.4	13
63	A 67-Year-Old Woman with BRCA 1 Mutation Associated with Pancreatic Adenocarcinoma. Journal of Gastrointestinal Cancer, 2011, 42, 160-164.	0.6	12
64	Reverse-Contrast Imaging and Targeted Radiation Therapy of Advanced Pancreatic Cancer Models. International Journal of Radiation Oncology Biology Physics, 2015, 93, 444-453.	0.4	12
65	Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma. Cancers, 2018, 10, 467.	1.7	12
66	New Approaches to the Treatment of Pancreatic Cancer. BioDrugs, 2011, 25, 207-216.	2.2	10
67	Genomics and pharmacogenomics of pancreatic adenocarcinoma. Pharmacogenomics Journal, 2012, 12, 1-9.	0.9	10
68	Visceral Thromboses in Pancreas Adenocarcinoma: Systematic Review. Clinical Colorectal Cancer, 2018, 17, e207-e216.	1.0	9
69	Non-invasive detection of acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations.. Journal of Clinical Oncology, 2019, 37, 4096-4096.	0.8	9
70	Liver and Bile Duct Cancer. , 2020, , 1314-1341.e11.		8
71	Modern oncological and operative outcomes in oesophageal cancer: the St. Jamesâ€™s hospital experience. Irish Journal of Medical Science, 2021, 190, 297-305.	0.8	8
72	Young patients with synchronous colorectal liver metastases. Journal of Surgical Oncology, 2016, 113, 473-476.	0.8	6

#	ARTICLE	IF	CITATIONS
73	A phase I trial of binimetinib in combination with gemcitabine (G) and cisplatin (C) patients (pts) with untreated advanced biliary cancer (ABC).. Journal of Clinical Oncology, 2015, 33, e15125-e15125.	0.8	6
74	A phase I/II trial of MEK162 in combination with gemcitabine (G) and cisplatin (C) for patients (pts) with untreated advanced biliary cancer (ABC).. Journal of Clinical Oncology, 2017, 35, 290-290.	0.8	6
75	A bi-institutional phase II study of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (Dex) combined with systemic gemcitabine and oxaliplatin (GemOx) for unresectable intrahepatic cholangiocarcinoma (ICC).. Journal of Clinical Oncology, 2018, 36, 4092-4092.	0.8	6
76	DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives. Frontiers in Cell and Developmental Biology, 2021, 9, 749490.	1.8	6
77	Liver and Bile Duct Cancer. , 2014, , 1373-1396.e8.		5
78	Pancreatic cancer: the role of molecular markers in diagnosis and management. Clinical Advances in Hematology and Oncology, 2011, 9, 900-8.	0.3	5
79	Texture analysis for survival prediction of pancreatic ductal adenocarcinoma patients with neoadjuvant chemotherapy. , 2016, , .		4
80	Case report: primary acinar cell carcinoma of the liver treated with multimodality therapy. Journal of Gastrointestinal Oncology, 2017, 8, E65-E72.	0.6	4
81	Inhibition of poly (ADP-ribose) polymerase-1 (PARP-1) to increase radiosensitivity of human pancreatic cancer (PAC) cell lines proficient in homology-directed repair (HDR).. Journal of Clinical Oncology, 2012, 30, 204-204.	0.8	4
82	Treatment, outcomes, and clinical trial participation in very elderly patients (pts) with metastatic pancreas cancer (mPC).. Journal of Clinical Oncology, 2014, 32, 4119-4119.	0.8	4
83	Evaluation of PARP inhibition as a platinum sparing strategy in Brca2-deficient pancreatic tumors.. Journal of Clinical Oncology, 2014, 32, e15237-e15237.	0.8	4
84	Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis.. Journal of Clinical Oncology, 2016, 34, e15636-e15636.	0.8	4
85	Prospective assessment for pathogenic germline alterations (PGA) in pancreas cancer (PAC).. Journal of Clinical Oncology, 2017, 35, 4102-4102.	0.8	4
86	Single agent HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLe ^x , in patients with pancreatic cancer and other CA19-9 positive malignancies.. Journal of Clinical Oncology, 2017, 35, 4110-4110.	0.8	4
87	Phase 2, open-label, multicenter study of the efficacy and safety of INCB054828 in patients (pts) with advanced, metastatic, or surgically unresectable cholangiocarcinoma (CCA) with inadequate response to prior therapy.. Journal of Clinical Oncology, 2017, 35, TPS4145-TPS4145.	0.8	4
88	Pilot study of gemcitabine, nab-paclitaxel, PEGPH20, and rivaroxaban for advanced pancreatic adenocarcinoma: An interim analysis.. Journal of Clinical Oncology, 2018, 36, 405-405.	0.8	4
89	A case of synchronous pancreatic ductal adenocarcinoma and ovarian mucinous cystic neoplasm: use of kras mutation molecular phenotyping to demonstrate independent primary origin. Gastrointestinal Cancer Research: GCR, 2012, 5, 67-70.	0.8	4
90	Genotype-phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer. British Journal of Cancer, 2020, 122, 293-294.	2.9	3

#	ARTICLE	IF	CITATIONS
91	Prevalence of pancreaticobiliary cancers in Irish families with pathogenic BRCA1 and BRCA2 variants. <i>Familial Cancer</i> , 2021, 20, 97-101.	0.9	3
92	Platinum-based combination therapy (PCT) and outcomes for patients (pts) with mixed hepatocellular carcinoma and intrahepatic cholangiocarcinoma (mHCC/ICC).. <i>Journal of Clinical Oncology</i> , 2015, 33, e15146-e15146.	0.8	3
93	Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 437-437.	0.8	3
94	Pharmacokinetic/pharmacodynamic (PK/PD) profile of AG-120 in patients with IDH1-mutant cholangiocarcinoma from a phase 1 study of advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4082-4082.	0.8	3
95	Feasibility and results of a randomized phase III study of fractionated ⁹⁰ Y-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having two or more prior therapies.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4026-4026.	0.8	3
96	Gastrointestinal Cancer Educational Case Series: Management of Metastatic Adenocarcinoma of Unknown Primary Origin in a Ph+ ALL Survivor. <i>Journal of Gastrointestinal Cancer</i> , 2011, 42, 165-170.	0.6	2
97	A Man with Klinefelter's Syndrome and New Abdominal Distension: A Discussion of Evaluation and Management. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 314-318.	0.6	2
98	Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 475-481.	1.4	2
99	Abstract CT026: Phase I trial of HuMab-5B1 (MVT-5873), a novel monoclonal antibody targeting sLea, in patients with advanced pancreatic cancer and other CA19-9 positive malignancies. , 2016, , .		2
100	Phase II trial of veliparib (V) in patients (pts) with previously treated BRCA or PALB2-mutated (mut) pancreas adenocarcinoma (PC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 358-358.	0.8	2
101	Clinical characterization of pancreatic ductal adenocarcinomas (PDAC) with mismatch repair (MMR) gene mutations.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15791-e15791.	0.8	2
102	Plasma KRAS as a biomarker for pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 316-316.	0.8	2
103	Communication and palliative care in a 64-year-old man with pancreatic adenocarcinoma. <i>Gastrointestinal Cancer Research: GCR</i> , 2012, 5, 130-4.	0.8	2
104	Patient knowledge, personal experience, and impact of the first wave of the COVID-19 pandemic in an Irish oncology cohort. <i>Irish Journal of Medical Science</i> , 2022, , 1.	0.8	2
105	A Woman with Remotely Treated Pancreas Cancer and New Abdominal Pain: A Discussion of Evaluation and Management. <i>Journal of Gastrointestinal Cancer</i> , 2011, 42, 236-240.	0.6	1
106	A pilot study of gemcitabine, nab-paclitaxel, PEGPH20 (PAG) and rivaroxaban for advanced pancreatic adenocarcinoma: Interim safety and efficacy analysis. <i>Annals of Oncology</i> , 2018, 29, viii248.	0.6	1
107	Clinical outcomes in pancreatic adenocarcinoma (PAC) in breast cancer (BC) survivors.. <i>Journal of Clinical Oncology</i> , 2010, 28, 4152-4152.	0.8	1
108	Clinical outcomes in pancreatic adenocarcinoma (PAC) associated with a known BRCA mutation.. <i>Journal of Clinical Oncology</i> , 2011, 29, 268-268.	0.8	1

#	ARTICLE	IF	CITATIONS
109	Hepatocellular carcinoma (HCC) and bone metastases (Mets).. Journal of Clinical Oncology, 2015, 33, e15129-e15129.	0.8	1
110	Analysis of prior malignancies in patients with cholangiocarcinoma.. Journal of Clinical Oncology, 2017, 35, 305-305.	0.8	1
111	A phase I study of mFOLFOX6 and ADI-PEG-20 in patients (pts) with advanced hepatocellular carcinoma (HCC) and other gastrointestinal (GI) malignancies.. Journal of Clinical Oncology, 2017, 35, 384-384.	0.8	1
112	Molecular Chaperones and How Addiction Matters in Cancer Therapy. , 2013, , 181-203.		1
113	Molecular features of BRCA1/2 and PALB2 mutation associated pancreatic cancer (PAC).. Journal of Clinical Oncology, 2014, 32, 206-206.	0.8	1
114	Pharmacogenomic modeling of pancreatic cancer (PDAC) for prediction of chemotherapy response and resistance in second-line treatment setting.. Journal of Clinical Oncology, 2014, 32, 4130-4130.	0.8	1
115	Genomic profiling of pancreas ductal adenocarcinoma (PDA), actionability, and correlation with clinical phenotype.. Journal of Clinical Oncology, 2016, 34, 4127-4127.	0.8	1
116	Comprehensive molecular profiling and analysis of mutual exclusivity of genetic aberrations (MEGA) of intra- and extrahepatic cholangiocarcinomas (IHC and EHC) evaluation of prognostic features and potential targets for intervention.. Journal of Clinical Oncology, 2016, 34, 4088-4088.	0.8	1
117	Visceral thromboses (VT) in pancreas adenocarcinoma (PDAC): A systematic review.. Journal of Clinical Oncology, 2017, 35, 268-268.	0.8	1
118	Mutational profiling of resected intrahepatic cholangiocarcinoma.. Journal of Clinical Oncology, 2017, 35, e15675-e15675.	0.8	1
119	A prospective analysis of germline alterations (GA) in biliary tract cancer (BTC).. Journal of Clinical Oncology, 2017, 35, 4085-4085.	0.8	1
120	Abstract 2275: Detection of IDH1 mutations in plasma cell-free circulating tumor DNA (ctDNA) from patients with cholangiocarcinoma. , 2019, , .		1
121	A case of advanced gastric cancer. Gastrointestinal Cancer Research: GCR, 2012, 5, 59-63.	0.8	1
122	Targeted therapies for pancreatic adenocarcinoma. Minerva Chirurgica, 2009, 64, 501-19.	0.8	1
123	Gastrointestinal Cancer Educational Case Series: The History and Management of Complex Cases in GI Oncology. A 72 Year-Old Man with Metastatic Gastric Cancer. Journal of Gastrointestinal Cancer, 2011, 42, 46-49.	0.6	0
124	Neoadjuvant chemotherapy for adult osteosarcoma: Results of long term follow-up. Journal of Clinical Oncology, 2008, 26, 10543-10543.	0.8	0
125	Clinical outcomes in patients age 40 or younger at diagnosis of synchronous metastatic colorectal cancer.. Journal of Clinical Oncology, 2011, 29, 531-531.	0.8	0
126	Clinical outcomes in patients age 40 or younger at diagnosis of synchronous metastatic colorectal cancer: A 20-year experience at Memorial Sloan-Kettering Cancer Center.. Journal of Clinical Oncology, 2011, 29, e14050-e14050.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Phase II single-arm, single-institution trial of neoadjuvant gemcitabine and oxaliplatin treatment (NT) in patients (pts) with resectable pancreas adenocarcinoma (PC).. Journal of Clinical Oncology, 2011, 29, 4065-4065.	0.8	0
128	Identification of germline genetic mutations in patients with pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2013, 31, 159-159.	0.8	0
129	Use of pharmacogenomic modeling in pancreatic cancer for prediction of chemotherapy response and resistance.. Journal of Clinical Oncology, 2013, 31, 142-142.	0.8	0
130	Multiplatform molecular profiling of 2,400 pancreatic adenocarcinomas to identify targets for therapeutic intent.. Journal of Clinical Oncology, 2014, 32, 4136-4136.	0.8	0
131	Abstract B98: Final results of a randomized phase Ib study of fractionated 90Y-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having at least two prior therapies. , 2015, , .		0
132	Presentation, clinical behavior, outcomes and therapies for patients with advanced pancreas adenocarcinoma (PAC) who present with or develop ascites.. Journal of Clinical Oncology, 2016, 34, 209-209.	0.8	0
133	Overall survival and clinical characteristics of BRCA germline/somatic cholangiocarcinoma (CCA).. Journal of Clinical Oncology, 2016, 34, 244-244.	0.8	0
134	Genomic landscape of pancreatic adenocarcinoma: Does age matter?. Journal of Clinical Oncology, 2016, 34, 250-250.	0.8	0
135	Assessment of genomic alterations in adenosquamous carcinoma of the pancreas (ASCOP).. Journal of Clinical Oncology, 2016, 34, 261-261.	0.8	0
136	Identification of potentially actionable molecular alterations in advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2016, 34, e15635-e15635.	0.8	0
137	Do pancreatic cancer (PDA) stem cell markers predict biologic behavior?. Journal of Clinical Oncology, 2016, 34, 4112-4112.	0.8	0
138	Breast cancer resistance protein (ABCG2) as a potential biomarker for gemcitabine and nab-paclitaxel sensitivity.. Journal of Clinical Oncology, 2016, 34, 4129-4129.	0.8	0
139	Phase 1B trial of ADI-PEG 20 (A) plus nab-Paclitaxel (nab-P) and gemcitabine (gem) in subjects with advanced pancreatic cancer (APC).. Journal of Clinical Oncology, 2016, 34, e15756-e15756.	0.8	0
140	Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.. Journal of Clinical Oncology, 2017, 35, 353-353.	0.8	0
141	Phase 1B trial of ADI-PEG 20 (A) plus nab-paclitaxel (nab-P) and gemcitabine (gem) in patients with advanced pancreatic cancer (PC).. Journal of Clinical Oncology, 2017, 35, 295-295.	0.8	0
142	Clinical impact of visceral thrombosis (VT) in pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2017, 35, 260-260.	0.8	0
143	Do pancreas cancer stem cells play crucial role in survival outcome?. Journal of Clinical Oncology, 2017, 35, e15721-e15721.	0.8	0
144	Impact of care at Memorial Sloan Kettering Cancer Center (MSKCC): A comprehensive cancer center on overall survival (OS) in patients (pts) with AJCC stage IV pancreas adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2017, 35, e18128-e18128.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Brain metastases (BM) in pancreatic ductal adenocarcinoma (PDAC): Clinical and molecular characteristics.. Journal of Clinical Oncology, 2017, 35, e15728-e15728.	0.8	0
146	Early-onset pancreatic ductal adenocarcinoma (PDAC) at Memorial Sloan Kettering Cancer Center (MSKCC).. Journal of Clinical Oncology, 2017, 35, e15736-e15736.	0.8	0
147	Abstract CT063: Phase 2, open-label, multicenter study of the efficacy and safety of INCB054828 in patients (pts) with advanced, metastatic, or surgically unresectable cholangiocarcinoma (CCA) with inadequate response to prior therapy. , 2017, , .		0
148	Prospective analysis of somatic and germline genetic alterations in patients with ampullary carcinomas.. Journal of Clinical Oncology, 2018, 36, 308-308.	0.8	0
149	Immunotherapy awareness in the oncology patient population: An Irish hospital experience.. Journal of Clinical Oncology, 2018, 36, e15160-e15160.	0.8	0
150	Prevalence of pancreaticobiliary cancer in Irish families with BRCA1 and BRCA2 mutations.. Journal of Clinical Oncology, 2019, 37, 210-210.	0.8	0
151	Hepatocellular carcinoma following renal transplantation. Gastrointestinal Cancer Research: GCR, 2011, 4, 180-3.	0.8	0
152	A 72-year-old man with duodenal adenocarcinoma. Gastrointestinal Cancer Research: GCR, 2012, 5, 93-6.	0.8	0
153	The role of novel biologics in biliary cancers. Minerva Gastroenterologica E Dietologica, 2016, 62, 325-339.	2.2	0
154	Targeting MET amplification in Gastro-oesophageal (GO) malignancies and overcoming MET inhibitor resistance: challenges and opportunities. Expert Review of Gastroenterology and Hepatology, 2022, 16, 601-624.	1.4	0